Cingulate Inc. (CING)Healthcare | Biotechnology | Kansas City, United States | NasdaqCM
6.35 USD
+0.32
(5.305%)
⇧
(April 21, 2026, 10:26 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:40 a.m. EDT
Despite accolades as a 'strong buy' with massive analyst price targets, the fundamentals remain a dangerous cash burn with negative earnings and a shrinking balance sheet; the recent 106% surge in short interest and ATM issuances indicate heavy dilution, while the price action effectively capped the recent rally near the 50-day average, suggesting a high-risk setup for any entry. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.128280 |
| MSTL | 0.132587 |
| AutoTheta | 0.134547 |
| AutoETS | 0.135686 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 0.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 350.214 |
| Market Cap | 77,789,856 |
| Forward P/E | -4.36 |
| Beta | -0.77 |
| Website | https://www.cingulate.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44951928 |
| Address1 | 1,901 West 47th Place |
| All Time High | 1,236.0 |
| All Time Low | 1.8 |
| Ask | 7.52 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 397,820 |
| Average Daily Volume3 Month | 492,983 |
| Average Volume | 492,983 |
| Average Volume10Days | 397,820 |
| Beta | -0.765 |
| Bid | 4.53 |
| Bid Size | 2 |
| Book Value | 0.346 |
| City | Kansas City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.3499 |
| Current Ratio | 1.164 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.4 |
| Day Low | 5.86 |
| Debt To Equity | 350.214 |
| Display Name | Cingulate |
| Ebitda | -19,397,214 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.503 |
| Enterprise Value | 67,953,712 |
| Eps Current Year | -1.8775 |
| Eps Forward | -1.455 |
| Eps Trailing Twelve Months | -4.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.696 |
| Fifty Day Average Change | -0.34610033 |
| Fifty Day Average Change Percent | -0.051687624 |
| Fifty Two Week Change Percent | 44.951927 |
| Fifty Two Week High | 11.89 |
| Fifty Two Week High Change | -5.5401006 |
| Fifty Two Week High Change Percent | -0.4659462 |
| Fifty Two Week Low | 3.2 |
| Fifty Two Week Low Change | 3.1498997 |
| Fifty Two Week Low Change Percent | 0.98434365 |
| Fifty Two Week Range | 3.2 - 11.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,638,973,800,000 |
| Float Shares | 11,292,081 |
| Forward Eps | -1.455 |
| Forward P E | -4.364192 |
| Free Cashflow | -10,425,198 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -9,774,057 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.35461 |
| Held Percent Institutions | 0.04659 |
| Implied Shares Outstanding | 12,250,564 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-08 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,161,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. |
| Long Name | Cingulate Inc. |
| Market | us_market |
| Market Cap | 77,789,856 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_1674914781 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -22,449,912 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 73,870,900 |
| Number Of Analyst Opinions | 5 |
| Open | 6.12 |
| Operating Cashflow | -17,245,182 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 913 942 2300 |
| Previous Close | 6.03 |
| Price Eps Current Year | -3.3821037 |
| Price Hint | 2 |
| Price To Book | 18.352312 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.064 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.31989956 |
| Regular Market Change Percent | 5.3051333 |
| Regular Market Day High | 6.4 |
| Regular Market Day Low | 5.86 |
| Regular Market Day Range | 5.86 - 6.4 |
| Regular Market Open | 6.12 |
| Regular Market Previous Close | 6.03 |
| Regular Market Price | 6.3499 |
| Regular Market Time | 1,776,781,563 |
| Regular Market Volume | 181,304 |
| Return On Assets | -0.83248 |
| Return On Equity | -4.50602 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 12,250,564 |
| Shares Percent Shares Out | 0.0912 |
| Shares Short | 1,078,595 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 464,009 |
| Short Name | Cingulate Inc. |
| Short Percent Of Float | 0.1122 |
| Short Ratio | 1.57 |
| Source Interval | 15 |
| State | KS |
| Symbol | CING |
| Target High Price | 55.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 28.702 |
| Target Median Price | 31.51 |
| Total Cash | 10,953,383 |
| Total Cash Per Share | 0.942 |
| Total Debt | 8,786,555 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.898375 |
| Two Hundred Day Average Change | 1.4515247 |
| Two Hundred Day Average Change Percent | 0.2963278 |
| Type Disp | Equity |
| Volume | 181,304 |
| Website | https://www.cingulate.com |
| Zip | 66,205 |